Evaluation of Demographic, Clinical Characteristics and Side Effects in Multiple Sclerosis Patients Vaccinated Against SARS-CoV-2 Virus

Evaluation of Demographic, Clinical Characteristics and Side Effects in Multiple Sclerosis Patients Vaccinated Against SARS-CoV-2 Virus

Objective: Our primary objective in our study was to review the side effect of MS patients vaccinated against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus from Istanbul University, Istanbul Faculty of Medicine, Multiple Sclerosis and Myelin Diseases Outpatient Clinic. The secon...

Full description

Bibliographic Details
Main Authors:	Özgü Kizek, Gizem Yağmur Yalçın, Tuncay Gündüz, Murat Kürtüncü, Mefküre Eraksoy
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2023-06-01
Series:	Türk Nöroloji Dergisi
Subjects:	multiple sclerosis sars-cov-2 vaccination side effects
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjn&un=TJN-97493

Similar Items

Evaluation of Depression and Anxiety of Patients with Multiple Sclerosis During the COVID-19 Pandemic: A Comparison with the General Population
by: Gizem Yağmur Yalçın, et al.
Published: (2021-12-01)

Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
by: Canan Duman İlki, et al.
Published: (2020-03-01)

Effect of smoking on disability progression in patients with multiple sclerosis
by: Tuncay Gündüz, et al.
Published: (2018-10-01)

Development of Multiple Sclerosis in Patients with Optic Neuritis: Analysis of Predictive Factors
by: Hacer Durmuş, et al.
Published: (2009-09-01)

The Predictive Role of NEDA in the Long-Term Course of Multiple Sclerosis
by: Özgü Kizek
Published: (2017-03-01)

Evaluation of the one-year effectiveness and side effects of rituximab in patients with multiple sclerosis in Kermanshah
by: Nazanin Razazian, et al.
Published: (2022-07-01)

Do steroids trigger mania in multiple sclerosis? Not always!
by: Serhan Sevim, et al.
Published: (2015-06-01)

Mortality in Patients with Multiple Sclerosis
by: Sümeyra Şamlı, et al.
Published: (2018-03-01)

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
by: Morteza Abdar, et al.
Published: (2017-03-01)

Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland
by: Agata Czarnowska, et al.
Published: (2022-06-01)

SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis
by: Amado Diaz de la Fe, et al.
Published: (2021-04-01)

Could SARS-CoV-2 herald a surge of multiple sclerosis?
by: Nevin Mohieldin Shalaby, et al.
Published: (2021-02-01)

Does Serum Vitamin D Level During Pregnancy Influence the Risk of Multiple Sclerosis?
by: Tuncay Gündüz
Published: (2016-12-01)

The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis
by: Angela Dziedzic, et al.
Published: (2021-02-01)

Demographic and clinical characteristics of familial and sporadic multiple sclerosis patients
by: Shahrzad Mokhtari, et al.
Published: (2023-01-01)

Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study
by: Firas Fneish, et al.
Published: (2023-12-01)

Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
by: Agustín Sancho-Saldaña, et al.
Published: (2022-04-01)

Multiple sclerosis /
by: 546326 Dobson, Ruth, et al.
Published: (2013)

Malignant multiple sclerosis: clinical and demographic prognostic factors
by: Fabrício Hampshire-Araújo, et al.

Adherence to disease-modifying therapies in patients with multiple sclerosis
by: Kołtuniuk A, et al.
Published: (2018-08-01)

Multiple sclerosis : recovery of function and neurorehabilitation /
by: Kesselring, Jurg, et al.
Published: (c201)

Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study
by: Agustín Sancho-Saldaña, et al.
Published: (2023-11-01)

SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation
by: Madison MacDougall, et al.
Published: (2022-04-01)

Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
by: Clara G. Chisari, et al.
Published: (2021-11-01)

Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based study
by: Mahdi Barzegar, et al.
Published: (2022-10-01)

A CASE OF COMBINED CENTRAL AND PERIPHERAL DEMYELINATION IN A PATIENT WITH PEDIATRIC MULTIPLE SCLEROSIS AFTER SARS-COV-2 VACCINATION
by: Angeloglou Stella, et al.
Published: (2022-12-01)

Immunocompetence after SARS-CoV-2 Infection in a Patient with Multiple Sclerosis Treated with Ofatumumab: A Case Report
by: Elżbieta Jasińska
Published: (2022-08-01)

New‐onset pemphigus foliaceus following SARS‐CoV‐2 infection and unmasking multiple sclerosis: A case report
by: Fatemeh Mohaghegh, et al.
Published: (2022-06-01)

Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study
by: Niklas Frahm, et al.
Published: (2023-05-01)

SARS-CoV-2-infection in the setting of autotransplants for multiple sclerosis
by: Juan Carlos Olivares-Gazca, et al.
Published: (2023-12-01)

Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study
by: Jorge Millán-Pascual, et al.
Published: (2023-12-01)

Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination
by: Maryam Golshani, et al.
Published: (2022-02-01)

Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
by: Kamila Zondra Revendova, et al.
Published: (2023-01-01)

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS
by: C. Solaro, et al.
Published: (2016-03-01)

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
by: Johann Sellner, et al.
Published: (2021-01-01)

Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
by: Agata Czarnowska, et al.
Published: (2022-05-01)

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
by: Maura Pugliatti, et al.
Published: (2022-10-01)

Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
by: Nicola Capasso, et al.
Published: (2020-12-01)

Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection
by: Antonia Pignolo, et al.
Published: (2021-12-01)

Autophagy in Multiple Sclerosis: Two Sides of the Same Coin
by: Chairi Misrielal, et al.
Published: (2020-11-01)